<DOC>
	<DOCNO>NCT02632721</DOCNO>
	<brief_summary>Phase I Dose Escalation : Primary objective determine MTD recommend dose Phase I Extension . Secondary objective investigate safety , pharmacokinetics efficacy BI 836858 combination decitabine Phase I Extension : Primary objective collect additional data safety , pharmacokinetics efficacy define Recommended Phase II Dose ( RP2D ) BI 836858 combination decitabine . Phase II : Primary objective investigate efficacy , safety pharmacokinetics BI 836858 combination decitabine compare decitabine monotherapy .</brief_summary>
	<brief_title>A Study Find Investigate Safe Dose BI 836858 Combination With Decitabine Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : Phase I Dose Escalation : 1 . Male female patient &gt; /= 18 year age relapse refractory AML 2 . Male female patient &gt; /= 65 year age previously untreated AML ineligible receive standard intensive therapy Phase I Extension Phase II : Male female patient &gt; /= 65 year age previously untreated AML ineligible receive standard intensive therapy Histologically cytologically confirm AML accord WHO classification Patients must eligible treatment decitabine Eastern cooperative oncology group ( ECOG ) performance score &lt; /=2 screen Further inclusion criterion apply Exclusion criterion : Acute promyelocytic leukemia ( APL , FrenchAmericanBritish ( FAB ) subtype M3 ) , accord WHO classification . Patients candidate allogeneic stem cell transplantation . Active chronic graft versus host disease require immunosuppressive treatment . Phase I extension Phase II : Prior treatment hypomethylating agent , prior treatment MDS . Prior treatment Cluster differentiation 33 ( CD33 ) antibody Furthr exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>